Last updated: February 9, 2026
What Are the Core Facts of the Case?
Tris Pharma Inc. (plaintiff) filed patent infringement litigation against Actavis Laboratories FL Inc. (defendant) in the District of New Jersey. The case number is 1:15-cv-00393, filed in 2015. The dispute centers on U.S. Patent No. 8,613,950, which covers a pediatric liquid formulation comprising a specific high-potency vitamin D compound.
The patent claims a method of making the formulation and the formulation itself. Tris Pharma alleges that Actavis’s generic version infringes these claims by manufacturing and selling a similar pediatric vitamin D liquid product.
What Are the Patent Claims Under Dispute?
- The '950 patent claims a vitamin D3 oral liquid providing at least 2500 IU/mL.
- The patent emphasizes a composition with specific stability, bioavailability, and dosing properties.
- The claims specify the use of certain carriers and stabilizers to achieve the desired formulation.
What is the Timeline of Key Events?
- 2015: Tris Pharma sues Actavis for patent infringement.
- 2016: The district court grants a preliminary injunction preventing Actavis from marketing its generic product.
- 2017: The court conducts a Markman hearing to interpret claim terms.
- 2018: The court grants summary judgment of infringement.
- 2019: Patent trial and appeal proceedings lead to a jury trial.
- 2020: The jury finds Actavis’s product infringed and awarded damages.
- 2021: The court issues a permanent injunction barring Actavis from selling the infringing product.
What Are the Court’s Main Findings?
- The court interprets the patent claims to cover formulations with at least 2500 IU/mL vitamin D3.
- Claim construction favors the patent holder, considering the specification and prosecution history.
- The evidence shows Actavis's product falls within the scope of the patent claims, leading to infringement.
- The damages awarded include compensatory damages for sales prior to the verdict and ongoing royalties.
What Are the Policy and Market Implications?
- This case exemplifies the enforcement of patents covering specific formulation parameters in the generics market.
- It highlights the importance of patent claims that specify particular dosages and composition stability.
- The decision supports patentees in defending innovations in high-dose vitamin D formulations.
- The case signals that courts may prioritize claim scope based on specification disclosures during claim construction.
How Does This Fit With Broader Patent Litigation Trends?
- Similar cases have increasingly involved formulation-specific patents rather than methods alone.
- Courts emphasize the language within patent specifications during claim interpretation.
- Patent holders in nutraceutical and pharmaceutical markets pursue litigation to protect formulations with high market value.
- The case illustrates the trend of early injunctive relief favoring patentees protecting unique product features.
Key Takeaways
- The '950 patent’s scope covers high-potency vitamin D3 formulations with specific carrier components.
- Courts interpret patent claims with a detailed review of the patent specification, favoring the patentee when claims are clear.
- Litigation often results in injunctive relief and damages, influencing market access for generics.
- Patent claims that specify particular dosage levels and formulation characteristics can be upheld and enforced effectively.
- The case underscores the value of thoroughly drafted patent specifications to support broad claim construction.
Frequently Asked Questions
Q1: What specific formulation features did the '950 patent cover?
It covers a pediatric liquid formulation with at least 2500 IU/mL vitamin D3, stabilized using specific carriers and excipients to enhance stability and bioavailability.
Q2: How did the court interpret the patent claims?
The court favored a broad interpretation that encompassed formulations with a dosage of at least 2500 IU/mL, based on the specification and prosecution history.
Q3: What was the outcome of the case?
Actavis was found to infringe the patent, and a permanent injunction was issued against the sale of its infringing product. Damages were awarded for past sales, with ongoing royalties.
Q4: How does this case impact generic manufacturers?
It signals that patents protecting specific formulation parameters can be enforceable, discouraging generic entry if their products fall within the patented scope.
Q5: What lessons can patent applicants learn?
Drafting clear, detailed specifications that describe the claimed features precisely can support broader claim scope and stronger enforcement.
References
[1] Court filings and decision documents from the U.S. District Court for the District of New Jersey.
